Finance
Novo and hims resolve dispute, will sell obesity drugs together, Bloomberg news reports
Published by Global Banking & Finance Review®
Posted on March 7, 2026
2 min readLast updated: March 7, 2026
Quick Summary
Novo Nordisk and Hims & Hers have resolved their recent dispute and will jointly sell obesity drugs via Hims’s platform, ending a legal confrontation that began in June 2025 over compounded knock‑off versions of Wegovy.
Novo and Hims to sell obesity drugs together as feud ends, Bloomberg News reports
Novo Nordisk and Hims & Hers Health End Dispute and Form Partnership
Background of the Dispute
March 6 (Reuters) - Wegovy maker Novo Nordisk plans to sell its weight-loss drugs on Hims & Hers Health platform, bringing an end to a dispute between the two companies that escalated into a legal battle last month, Bloomberg News reported on Friday.
Market Reaction
Hims shares surged 39% in after-hours trading after the report.
Legal and Regulatory Issues
The report comes nearly a month after Novo sued Hims over patent infringement following the U.S. telehealth firm's launch, and then cancellation, of a $49 copy of Novo's obesity pill.
The U.S. Food and Drug Administration had also threatened action against Hims.
Details of the New Partnership
Announcement Timeline
Novo and Hims plan to announce a new partnership as soon as Monday, the report said, citing a person familiar with the matter.
Previous Agreements and Marketing Concerns
Last year, Novo ended a short-lived agreement to sell its Wegovy weight-loss drug through Hims over the company's marketing tactics and continued sales of Wegovy copies.
Statements from Both Companies
A Novo spokesperson said in an e-mailed statement the company is "always in conversation with companies that can help improve patient access to FDA-approved medicines".
Hims did not immediately respond to a request for comment.
Reporting Credits
(Reporting by Carlos Méndez in Mexico City, additional reporting by Mihika Sharma in Bengaluru; Editing by Himani Sarkar)
Key Takeaways
- •The renewed collaboration follows a dramatic breakup in June 2025 when Novo ended the partnership over Hims’s alleged mass sale of unauthorized compounded Wegovy versions, which Novo called deceptive and unsafe (cnbc.com).
- •In early 2026, Hims launched a lower‑cost, unapproved Wegovy pill, prompting Novo Nordisk to vow legal and regulatory action and the FDA to signal crackdown on such copycat obesity drugs (apnews.com).
- •The new agreement will allow Wegovy and related obesity treatments to be sold on the Hims & Hers platform again—likely under stricter compliance with FDA-approved formulations and marketing practices.
References
Frequently Asked Questions about Novo and Hims resolve dispute, will sell obesity drugs together, Bloomberg News reports
1What companies resolved their dispute over weight-loss drugs?
Novo Nordisk and Hims & Hers Health settled their legal dispute over selling weight-loss drugs.
2What is the outcome of the Novo and Hims legal battle?
Novo Nordisk and Hims plan to announce a partnership to sell obesity drugs together.
3Which weight-loss drug will be available on the Hims platform?
Wegovy, made by Novo Nordisk, will be available on the Hims & Hers Health platform.
4When will the Novo and Hims partnership be announced?
The partnership is expected to be announced as soon as Monday, according to sources.
5Who reported the Novo and Hims partnership news?
Bloomberg News reported the planned partnership between Novo Nordisk and Hims & Hers Health.